Patents by Inventor Shiyong GONG

Shiyong GONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250002594
    Abstract: Provided are antibodies capable of binding CD122, antibodies capable of binding CD132, and bispecific CD122/CD132 binding proteins in FIT-Ig or duobody format prepared with antigen binding fragments thereof. The antibodies and bispecific binding proteins are useful for treating or preventing diseases such as T cell dysfunctional disorders or cancers.
    Type: Application
    Filed: October 24, 2022
    Publication date: January 2, 2025
    Inventors: Shiyong GONG, Lini HUANG, Chengbin WU, Danqing WU, Xuan WU, Rui ZHANG
  • Patent number: 12060425
    Abstract: High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 and anti-LAG-3 antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both PD-1 and LAG-3 simultaneously. Such bispecific FIT-Ig binding proteins are useful for treatment of cancer.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: August 13, 2024
    Assignee: SHANGHAI EPIMAB BIOTHERAPEUTICS CO., LTD.
    Inventors: Xuan Wu, Shiyong Gong, Chengbin Wu
  • Publication number: 20240010753
    Abstract: Provided herein are antibodies recognizing receptor tyrosine kinase-like orphan receptor 1 (ROR1), bispecific ROR1/CD3 binding proteins such as FIT-Ig and MAT-Fab binding proteins, and the use of the antibodies and bispecific binding proteins for treating hematopoietic cancers and solid tumors.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 11, 2024
    Inventors: Shiyong Gong, Kedong OUYANG, Chengbin Wu, Danqing Wu, Xuan Wu, Rui Zhang
  • Publication number: 20230295313
    Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.
    Type: Application
    Filed: June 22, 2020
    Publication date: September 21, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: John G. Emery, Qi Fei, Shiyong Gong, Sanjay Kumar, Fang Ren, Teddy Yang, Hua Ying
  • Publication number: 20230242675
    Abstract: The present invention relates to bispecific binding proteins that bind TGF? and PD-L1, and novel anti-PD-L1 antibodies, methods of making the bispecific binding proteins and antibodies, compositions comprising the bispecific binding proteins or antibodies, and methods of using the bispecific binding proteins for blocking TGF?-mediated suppression of T cell activation, for blocking PD-L1-mediated suppression of T cell activation, and for treating cancer.
    Type: Application
    Filed: November 27, 2020
    Publication date: August 3, 2023
    Inventors: Shiyong Gong, Xuan Wu, Chengbin Wu
  • Patent number: 11608384
    Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: March 21, 2023
    Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Ying Zhang, Shiyong Gong, Xiaolan Sun, Tengjiao Xu, Fei Peng, Yuzhu Chen, Lile Liu
  • Publication number: 20230002489
    Abstract: High-affinity antibodies recognizing CD3 and B Cell Maturation Factor protein (BCMA) are disclosed. Binding sites from humanized anti-CD3 and anti-BCMA antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both CD3 and BCMA simultaneously. Such antibodies, antigen-binding portions thereof, and bispecific FIT-Ig binding proteins are useful for treating cancer.
    Type: Application
    Filed: November 26, 2020
    Publication date: January 5, 2023
    Inventors: Chengbin WU, Danqing WU, Lini HUANG, Amin ZHANG, Zhengrong SHUAI, Rui ZHANG, Shiyong GONG, Xuan WU
  • Publication number: 20220389111
    Abstract: High-affinity antibodies recognizing CD39 are disclosed. The antibodies are capable of neutralizing ATPase activity of CD39 on CD-39 expressing cells. Such antibodies are useful for treatment of cancers and other disorders mediated by CD39 activity.
    Type: Application
    Filed: October 11, 2019
    Publication date: December 8, 2022
    Inventors: Fang REN, Shiyong GONG, Chengbin WU
  • Publication number: 20220017617
    Abstract: Bispecific Fabs-In-Tandem Immunoglobulin (FTT-Ig) binding proteins that bind both EGFR and PD-L1 simultaneously are disclosed. Such bispecific EGFR/PD-L1 FIT-Ig binding proteins are efficiently expressed and are useful for blocking EGFR signaling, for blocking PD-L1 signaling, and for treating cancer.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 20, 2022
    Applicant: SHANGHAI EPIMAB BIOTHERAPEUTICS CO., LTD.
    Inventors: Chengbin WU, Shiyong GONG
  • Publication number: 20210347873
    Abstract: A BLyS antibody, preparation method therefor and application thereof, the BLyS antibody comprising one or more of CDR1, CDR2 and CDR3 of a heavy chain variable region of the BLyS antibody, and/or one or more of CDR1, CDR2 and CDR3 of a light chain variable region of the BLyS antibody. An amino acid sequence of the antibody is shown in a sequence listing. The BLyS antibody has a high affinity, and may observably and effectively seal a BLyS protein at a protein level and a cell level, and prevent the BLyS protein from binding to a receptor. The BLyS antibody lacks a cross-reaction with homologous protein antigens such as human APRIL, and enjoys good biological activity. The BLyS antibody may inhibit the proliferation of human BLyS-induced mouse B cells and may therefore be used for preparing a drug for preventing or treating diseases associated with BLyS expression or dysfunction.
    Type: Application
    Filed: July 5, 2017
    Publication date: November 11, 2021
    Inventors: Xiaodan CAO, Yingying HU, Fang REN, Shiyong GONG, Jing GONG, Qiang LV, Hongzhuan GU, Beilei SHI, Xiaohui SHAO, Xiaofen LV, Stewart LEUNG, Lile LIU
  • Patent number: 11136387
    Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 5, 2021
    Assignee: SHANGHAI PHARMAEXPLORER CO., LTD.
    Inventors: Yizhen Yang, Shiyong Gong, Lijuan Hao, Jian Wu, Xinxiu Yang, Qin Zhong, Shaoping Hu, Stewart Leung, Qing Duan, Lile Liu
  • Publication number: 20210198377
    Abstract: The present invention provides a TPBG antibody, a preparation method thereof, conjugates and use thereof. The TPBG antibody comprises one or more of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 of the heavy chain variable region of TPBG antibody, and/or one or more of the light chain CDR1, the light chain CDR2 and the light chain CDR3 of the light chain variable region of TPBG antibody, and the amino acid sequences of which are described in the present invention. The TPBG antibody is humanized antibody with high affinity, and the conjugates prepared by coupling the TPBG antibody with the small-molecule drug toxin MMAF can have a cytotoxicity effects on TPBG-positive cells, therefore the TPBG antibody can be used in the preparation of drugs for treating tumors and the like.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 1, 2021
    Applicant: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Xiaolan SUN, Ying ZHANG, Yu ZHANG, Feifei HU, Shiyong GONG, Lile LIU
  • Publication number: 20210188980
    Abstract: High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 and anti-LAG-3 antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both PD-1 and LAG-3 simultaneously. Such bispecific FIT-Ig binding proteins are useful for treatment of cancer.
    Type: Application
    Filed: April 30, 2019
    Publication date: June 24, 2021
    Applicant: SHANGHAI EPIMAB BIOTHERAPEUTICS CO., LTD.
    Inventors: Xuan WU, Shiyong GONG, Chengbin WU
  • Publication number: 20200062856
    Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.
    Type: Application
    Filed: April 4, 2018
    Publication date: February 27, 2020
    Applicant: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Ying Zhang, Shiyong Gong, Xiaolan Sun, Tengjiao Xu, Fei Peng, Yuzhu Chen, Lile Liu
  • Publication number: 20190309059
    Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 10, 2019
    Applicant: SHANGHAI PHARMAEXPLORER CO., LTD.
    Inventors: Yizhen YANG, Shiyong GONG, Lijuan HAO, Jian WU, Xinxiu YANG, Qin ZHONG, Shaoping HU, Stewart LEUNG, Qing DUAN, Lile LIU